{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:15:02Z","timestamp":1788225302777,"version":"build-2803163510"},"reference-count":132,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clinre.2026.102874","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:07:46Z","timestamp":1782601666000},"page":"102874","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["TACE-induced liver injury in hepatocellular carcinoma: mechanisms, prediction, and prevention in the era of gut microbiota and inflammasome research"],"prefix":"10.1016","volume":"50","author":[{"given":"Kai","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuge","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4680-7137","authenticated-orcid":false,"given":"Huanzhang","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"03","key":"10.1016\/j.clinre.2026.102874_bib0001","doi-asserted-by":"crossref","DOI":"10.1142\/S1793545825300046","article-title":"Activatable fluorescent probes for imaging and diagnosis of hepatocellular carcinoma","volume":"18","author":"Men","year":"2025","journal-title":"J Innov Opt Health Sci"},{"issue":"12","key":"10.1016\/j.clinre.2026.102874_bib0002","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/jvh.13886","article-title":"CHB patients with rtA181T-mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes","volume":"30","author":"Ning","year":"2023","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.clinre.2026.102874_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.156094","article-title":"A multi-omic analysis reveals that Gamabufotalin exerts anti-hepatocellular carcinoma effects by regulating amino acid metabolism through targeting STAMBPL1","volume":"135","author":"Zheng","year":"2024","journal-title":"Phytomedicine"},{"issue":"2","key":"10.1016\/j.clinre.2026.102874_bib0004","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jceh.2022.11.014","article-title":"Indian national association for study of the liver (INASL) guidance paper on nomenclature, diagnosis and treatment of nonalcoholic fatty Liver disease (NAFLD)","volume":"13","author":"Duseja","year":"2023","journal-title":"J Clin Exp Hepatol"},{"issue":"8","key":"10.1016\/j.clinre.2026.102874_bib0005","article-title":"Incidence and risk factors for postoperative delirium after liver transplantation: a systematic review and meta-analysis","volume":"25","author":"Zhou","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"10.1016\/j.clinre.2026.102874_bib0006","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3390\/jcm14020314","article-title":"All you need to know about TACE: a comprehensive review of indications, techniques, efficacy, limits, and technical advancement","volume":"14","author":"Lanza","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.clinre.2026.102874_bib0007","series-title":"TACE side effects and complications","first-page":"119","author":"Nardis","year":"2023"},{"issue":"12","key":"10.1016\/j.clinre.2026.102874_bib0008","doi-asserted-by":"crossref","first-page":"7511","DOI":"10.62347\/PLQF5135","article-title":"Development and verification of a nomogram for predicting portal vein tumor thrombosis in hepatocellular carcinoma","volume":"16","author":"Liu","year":"2024","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.clinre.2026.102874_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113993","article-title":"Disorders of cancer metabolism: the therapeutic potential of cannabinoids","volume":"157","author":"Sun","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.clinre.2026.102874_bib0010","article-title":"Development and validation of a predictive model for liver failure after transarterial chemoembolization using gadoxetic acid-enhanced MRI and functional liver imaging score","author":"Wu","year":"2025","journal-title":"Acad Radiol"},{"issue":"24","key":"10.1016\/j.clinre.2026.102874_bib0011","doi-asserted-by":"crossref","first-page":"8535","DOI":"10.12998\/wjcc.v10.i24.8535","article-title":"Identification of predictive factors for post-transarterial chemoembolization liver failure in hepatocellular carcinoma patients: a retrospective study","volume":"10","author":"Yuan","year":"2022","journal-title":"World J Clin Cases"},{"issue":"10","key":"10.1016\/j.clinre.2026.102874_bib0012","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1007\/s00270-022-03233-9","article-title":"Initiative on superselective conventional transarterial chemoembolization results (INSPIRE)","volume":"45","author":"de Baere","year":"2022","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.clinre.2026.102874_bib0013","article-title":"Summary of the evidence of best practices for the prevention and treatment of embolism syndrome after TACE in primary liver cancer","volume":"13","author":"Yao","year":"2023","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.clinre.2026.102874_bib0014","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1007\/s10620-023-07984-4","article-title":"Predictors of liver dysfunction after transhepatic arterial chemo-embolization in hepatocellular carcinoma patients","volume":"68","author":"Cheng","year":"2023","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clinre.2026.102874_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2025.156796","article-title":"Precision strike strategy for liver diseases trilogy with Xiao-Chai-Hu decoction: a meta-analysis with machine learning","volume":"142","author":"Wang","year":"2025","journal-title":"Phytomedicine"},{"issue":"6","key":"10.1016\/j.clinre.2026.102874_bib0016","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jvir.2018.01.769","article-title":"Predicting treatment response to intra-arterial therapies for hepatocellular carcinoma with the use of supervised machine learning-an artificial intelligence concept","volume":"29","author":"Abajian","year":"2018","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"10.1016\/j.clinre.2026.102874_bib0017","doi-asserted-by":"crossref","DOI":"10.1148\/ryai.2019180021","article-title":"A machine learning model to predict hepatocellular carcinoma response to transcatheter arterial chemoembolization","volume":"1","author":"Morshid","year":"2019","journal-title":"Radiol Artif Intell"},{"key":"10.1016\/j.clinre.2026.102874_bib0018","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2147\/JHC.S334674","article-title":"Prediction of early treatment response to initial conventional transarterial chemoembolization therapy for hepatocellular carcinoma by machine-learning model based on computed tomography","volume":"8","author":"Dong","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"issue":"1","key":"10.1016\/j.clinre.2026.102874_bib0019","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40644-022-00457-3","article-title":"Real-time automatic prediction of treatment response to transcatheter arterial chemoembolization in patients with hepatocellular carcinoma using deep learning based on digital subtraction angiography videos","volume":"22","author":"Zhang","year":"2022","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.clinre.2026.102874_bib0020","article-title":"Deep learning predicts overall survival of patients with unresectable hepatocellular carcinoma treated by transarterial chemoembolization plus Sorafenib","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.clinre.2026.102874_bib0021","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2147\/JHC.S443660","article-title":"A deep learning model combining multimodal factors to predict the overall survival of transarterial chemoembolization","volume":"11","author":"Sun","year":"2024","journal-title":"J Hepatocell Carcinoma"},{"issue":"5","key":"10.1016\/j.clinre.2026.102874_bib0022","article-title":"ALBI grade: evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma","volume":"3","author":"Demirtas","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.clinre.2026.102874_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1002589","article-title":"Gut microbiota changes and biological mechanism in hepatocellular carcinoma after transarterial chemoembolization treatment","volume":"12","author":"Bian","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clinre.2026.102874_bib0024","article-title":"Insights into the gut-liver axis: mechanisms and emerging therapies in hepatocellular carcinoma","volume":"16","author":"Hu","year":"2025","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.clinre.2026.102874_bib0025","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.3390\/ijms25084537","article-title":"NLRP3 Inflammasome in acute and chronic liver diseases","volume":"25","author":"Sayaf","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinre.2026.102874_bib0026","article-title":"The role of NLRP3 inflammasome in hepatocellular carcinoma","volume":"14","author":"Zhao","year":"2023","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.clinre.2026.102874_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2024.102458","article-title":"Gut microbiota-NLRP3 inflammasome crosstalk in metabolic dysfunction-associated steatotic liver disease","volume":"48","author":"Yu","year":"2024","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.clinre.2026.102874_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2024.108198","article-title":"Identification of cuproptosis-related lncRNAs with the significance in prognosis and immunotherapy of oral squamous cell carcinoma","volume":"171","author":"Gong","year":"2024","journal-title":"Comput Biol Med"},{"issue":"5","key":"10.1016\/j.clinre.2026.102874_bib0029","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3390\/antiox11050870","article-title":"NLRP3 Inflammasome and pyroptosis in liver pathophysiology: the emerging relevance of Nrf2 inducers","volume":"11","author":"Hurtado-Navarro","year":"2022","journal-title":"Antioxidants (Basel)"},{"issue":"1","key":"10.1016\/j.clinre.2026.102874_bib0030","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13020-023-00745-5","article-title":"A novel microbial and hepatic biotransformation-integrated network pharmacology strategy explores the therapeutic mechanisms of bioactive herbal products in neurological diseases: the effects of Astragaloside IV on intracerebral hemorrhage as an example","volume":"18","author":"Hu","year":"2023","journal-title":"Chin Med"},{"issue":"12","key":"10.1016\/j.clinre.2026.102874_bib0031","doi-asserted-by":"crossref","first-page":"5897","DOI":"10.1007\/s11010-025-05359-z","article-title":"The gut microbiota-NLRP3 inflammasome connection: current evidence and perspectives for non-communicable diseases","volume":"480","author":"Mafra","year":"2025","journal-title":"Mol Cell Biochem"},{"issue":"23","key":"10.1016\/j.clinre.2026.102874_bib0032","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.3390\/cells11233758","article-title":"NLRP3 and gut microbiota homeostasis: progress in research","volume":"11","author":"Pan","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.clinre.2026.102874_bib0033","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.clinre.2026.102874_bib0034","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.clinre.2026.102874_bib0035","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s00270-021-02968-1","article-title":"CIRSE standards of practice on Hepatic transarterial chemoembolisation","volume":"44","author":"Lucatelli","year":"2021","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"10.1016\/j.clinre.2026.102874_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.17998\/jlc.2022.11.07","article-title":"2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma","volume":"23","year":"2023","journal-title":"J Liver Cancer"},{"key":"10.1016\/j.clinre.2026.102874_bib0037","article-title":"Transarterial chemoembolization for hepatocellular carcinoma: current role and techniques","volume":"10","author":"Tanaka","year":"2025","journal-title":"Interv Radiol (Higashimatsuyama)"},{"issue":"7","key":"10.1016\/j.clinre.2026.102874_bib0038","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jvir.2023.03.020","article-title":"Radioembolization for treatment of hepatocellular carcinoma: current evidence and patterns of utilization","volume":"34","author":"Briody","year":"2023","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"10.1016\/j.clinre.2026.102874_bib0039","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1097\/TP.0000000000005204","article-title":"Transarterial radioembolization can downstage intermediate and advanced hepatocellular carcinoma to liver transplantation","volume":"109","author":"Berardi","year":"2025","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.clinre.2026.102874_bib0040","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/SLA.0000000000006061","article-title":"Resection postradioembolization in patients with single large hepatocellular carcinoma","volume":"278","author":"Tzedakis","year":"2023","journal-title":"Ann Surg"},{"issue":"7","key":"10.1016\/j.clinre.2026.102874_bib0041","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/cncr.23339","article-title":"Liver disease induced by radioembolization of liver tumors: description and possible risk factors","volume":"112","author":"Sangro","year":"2008","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clinre.2026.102874_bib0042","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/hep.26191","article-title":"Prognostic factors and prevention of radioembolization-induced liver disease","volume":"57","author":"Gil-Alzugaray","year":"2013","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.clinre.2026.102874_bib0043","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/MEG.0000000000000772","article-title":"Radioembolization-induced liver disease: a systematic review","volume":"29","author":"Braat","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2026.102874_bib0044","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3348\/kjr.2022.0510","article-title":"2022 Korean liver cancer association-national cancer center korea practice guidelines for transarterial therapy of hepatocellular carcinoma: what's new?","volume":"24","author":"Lee","year":"2023","journal-title":"Korean J Radiol"},{"issue":"1","key":"10.1016\/j.clinre.2026.102874_bib0045","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.clinre.2026.102874_bib0046","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jvir.2017.04.025","article-title":"Quality improvement guidelines for transarterial chemoembolization and embolization of hepatic malignancy","volume":"28","author":"Gaba","year":"2017","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"10.1016\/j.clinre.2026.102874_bib0047","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3348\/jksr.2025.0028","article-title":"LI-RADS CT\/MRI treatment response assessment update in 2024","volume":"86","author":"Shin","year":"2025","journal-title":"J Korean Soc Radiol"},{"issue":"6","key":"10.1016\/j.clinre.2026.102874_bib0048","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3390\/medicina59061121","article-title":"Added value of cone-beam computed tomography for detecting hepatocellular carcinomas and feeding arteries during transcatheter arterial chemoembolization focusing on radiation exposure","volume":"59","author":"Kim","year":"2023","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"10.1016\/j.clinre.2026.102874_bib0049","doi-asserted-by":"crossref","first-page":"052","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"issue":"7","key":"10.1016\/j.clinre.2026.102874_bib0050","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1007\/s00330-024-11272-8","article-title":"Degradable starch microspheres transarterial chemoembolization (DSM-TACE) in patients with unresectable hepatocellular carcinoma: results from the prospective multicenter observational hepastar trial","volume":"35","author":"Collettini","year":"2025","journal-title":"Eur Radiol"},{"issue":"11","key":"10.1016\/j.clinre.2026.102874_bib0051","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.diii.2022.06.007","article-title":"Liver imaging reporting and data system (LI-RADS) v2018: reliability and agreement for assessing hepatocellular carcinoma locoregional treatment response","volume":"103","author":"Abdelrahman","year":"2022","journal-title":"Diagn Interv Imaging"},{"issue":"1","key":"10.1016\/j.clinre.2026.102874_bib0052","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"issue":"2","key":"10.1016\/j.clinre.2026.102874_bib0053","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL clinical practice guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2026.102874_bib0054","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hep.28453","article-title":"Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data","volume":"64","author":"Lencioni","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.clinre.2026.102874_bib0055","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1186\/s12885-019-5989-2","article-title":"Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study","volume":"19","author":"Miksad","year":"2019","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.clinre.2026.102874_bib0056","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1016\/j.acra.2024.12.068","article-title":"Development and validation of a predictive model for liver failure after transarterial chemoembolization using gadoxetic acid-enhanced MRI and functional liver imaging score","volume":"32","author":"Wu","year":"2025","journal-title":"Acad Radiol"},{"issue":"2","key":"10.1016\/j.clinre.2026.102874_bib0057","first-page":"241","article-title":"Identifying predictors and evaluating the role of steroids in the prevention of post-embolization syndrome after transarterial chemoembolization and bland embolization","volume":"34","author":"Agrawal","year":"2020","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.clinre.2026.102874_bib0058","series-title":"TACE and TARE Associated Complications in Liver Tumours","author":"Makki","year":"2024"},{"issue":"4","key":"10.1016\/j.clinre.2026.102874_bib0059","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3350\/cmh.2015.21.4.344","article-title":"Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future","volume":"21","author":"Woo","year":"2015","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"10.1016\/j.clinre.2026.102874_bib0060","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00330-016-4488-y","article-title":"Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion","volume":"27","author":"Monier","year":"2017","journal-title":"Eur Radiol"},{"issue":"4","key":"10.1016\/j.clinre.2026.102874_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2025.102538","article-title":"Transarterial chemoembolization: a consistent and continuously evolving therapy for hepatocellular carcinoma","volume":"15","author":"Mukund","year":"2025","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.clinre.2026.102874_bib0062","article-title":"Sterile inflammation in liver transplantation","volume":"10","author":"Kahan","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"10.1016\/j.clinre.2026.102874_bib0063","article-title":"Danger-associated molecular patterns (DAMPs): molecular triggers for sterile inflammation in the","volume":"19","author":"Mihm","year":"2018","journal-title":"Liver Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.clinre.2026.102874_bib0064","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.4049\/jimmunol.1302039","article-title":"NLRP3 regulates neutrophil functions and contributes to hepatic ischemia-reperfusion injury independently of inflammasomes","volume":"192","author":"Inoue","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.clinre.2026.102874_bib0065","article-title":"The role of NLRP3 inflammasome activation pathway of hepatic macrophages in liver ischemia-reperfusion injury","volume":"13","author":"Wu","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.clinre.2026.102874_bib0066","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.20632","article-title":"Bacterial translocation (BT) in cirrhosis","volume":"41","author":"Wiest","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.clinre.2026.102874_bib0067","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jhep.2013.07.044","article-title":"Pathological bacterial translocation in liver cirrhosis","volume":"60","author":"Wiest","year":"2014","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.clinre.2026.102874_bib0068","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/gutjnl-2012-302188","article-title":"TLR4 stresses the liver","volume":"61","author":"Sahin","year":"2012","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.clinre.2026.102874_bib0069","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/cimb47020079","article-title":"Advances in understanding lipopolysaccharide-mediated Hepatitis: mechanisms and pathological features","volume":"47","author":"Nakadate","year":"2025","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.clinre.2026.102874_bib0070","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jhep.2025.10.008","article-title":"Microbial metabolism dysfunction induced by transarterial chemoembolization aggravates postprocedural liver injury in HCC","volume":"84","author":"Li","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2026.102874_bib0071","doi-asserted-by":"crossref","first-page":"8277","DOI":"10.2147\/JIR.S532908","article-title":"NLRP3 Inflammasome activation in liver disorders: from molecular pathways to therapeutic strategies","volume":"18","author":"Ma","year":"2025","journal-title":"J Inflamm Res"},{"issue":"6","key":"10.1016\/j.clinre.2026.102874_bib0072","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clinre.2026.102874_bib0073","doi-asserted-by":"crossref","first-page":"32","DOI":"10.12809\/hkmj2311208","article-title":"Liver-and tumour-specific indicators predicting suboptimal survival following repeat transarterial chemoembolisation in patients with hepatocellular carcinoma","volume":"31","author":"Chen","year":"2025","journal-title":"Hong Kong Med J"},{"issue":"11","key":"10.1016\/j.clinre.2026.102874_bib0074","doi-asserted-by":"crossref","DOI":"10.5306\/wjco.v16.i11.112404","article-title":"Breaking through the transarterial chemoembolization resistance barrier: reshaping the treatment path for advanced liver cancer with triple therapy","volume":"16","author":"Shi","year":"2025","journal-title":"World J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clinre.2026.102874_bib0075","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/annonc\/mdt247","article-title":"A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer","volume":"24","author":"Kadalayil","year":"2013","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.clinre.2026.102874_bib0076","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/hep.26256","article-title":"The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma","volume":"57","author":"Sieghart","year":"2013","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.clinre.2026.102874_bib0077","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jhep.2014.11.014","article-title":"Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process","volume":"62","author":"Adhoute","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2026.102874_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijscr.2025.111283","article-title":"Common hepatic duct necrosis following transarterial chemoembolization for hepatocellular carcinoma: a case report and literature review","volume":"130","author":"Dao","year":"2025","journal-title":"Int J Surg Case Rep"},{"issue":"36","key":"10.1016\/j.clinre.2026.102874_bib0079","doi-asserted-by":"crossref","first-page":"8434","DOI":"10.12998\/wjcc.v11.i36.8434","article-title":"Post-trans-arterial chemoembolization hepatic necrosis and biliary stenosis: clinical charateristics and endoscopic approach","volume":"11","author":"Cocca","year":"2023","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.clinre.2026.102874_bib0080","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.avsg.2024.12.079","article-title":"Dexamethasone-based prophylactic therapy for prevention of post-embolization syndrome: a systematic review and meta-analysis assessing its efficacy and influence of dosage and timing in patients undergoing arterial embolization","volume":"113","author":"Raza","year":"2025","journal-title":"Ann Vasc Surg"},{"issue":"5","key":"10.1016\/j.clinre.2026.102874_bib0081","doi-asserted-by":"crossref","first-page":"890","DOI":"10.3748\/wjg.v29.i5.890","article-title":"Efficacy of dexamethasone and N-acetylcysteine combination in preventing post-embolization syndrome after transarterial chemoembolization in hepatocellular carcinoma","volume":"29","author":"Simasingha","year":"2023","journal-title":"World J Gastroenterol"},{"issue":"7","key":"10.1016\/j.clinre.2026.102874_bib0082","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.jvir.2023.02.011","article-title":"Hepatic abscess after liver-directed therapy","volume":"34","author":"Kumari","year":"2023","journal-title":"J Vasc Interv Radiol"},{"issue":"10","key":"10.1016\/j.clinre.2026.102874_bib0083","doi-asserted-by":"crossref","first-page":"1514.e5","DOI":"10.1016\/j.cmi.2021.01.014","article-title":"Association between prophylactic antibiotic use for transarterial chemoembolization and occurrence of liver abscess: a retrospective cohort study","volume":"27","author":"Yoshihara","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.clinre.2026.102874_bib0084","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jceh.2021.08.027","article-title":"Gut barrier and microbiota in cirrhosis","volume":"12","author":"Philips","year":"2022","journal-title":"J Clin Exp Hepatol"},{"issue":"6","key":"10.1016\/j.clinre.2026.102874_bib0085","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70119","article-title":"Surrogate markers of intestinal permeability, bacterial translocation and gut-vascular barrier damage across stages of cirrhosis","volume":"45","author":"Haedge","year":"2025","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.clinre.2026.102874_bib0086","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL clinical practice guidelines for the management of patients with decompensated cirrhosis","volume":"69","year":"2018","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.clinre.2026.102874_bib0087","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/hep.31884","article-title":"Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal Syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases","volume":"74","author":"Biggins","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.clinre.2026.102874_bib0088","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.clinre.2026.102874_bib0089","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1097\/HEP.0000000000000647","article-title":"AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis","volume":"79","author":"Kaplan","year":"2024","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.clinre.2026.102874_bib0090","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hep.27210","article-title":"Hepatic encephalopathy in chronic liver disease: 2014 practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver","volume":"60","author":"Vilstrup","year":"2014","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.clinre.2026.102874_bib0091","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.jhep.2021.09.003","article-title":"EASL clinical practice guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis","volume":"76","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2026.102874_bib0092","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2201159","article-title":"A distinct microbiota signature precedes the clinical diagnosis of hepatocellular carcinoma","volume":"15","author":"Yang","year":"2023","journal-title":"Gut Microbes"},{"issue":"8","key":"10.1016\/j.clinre.2026.102874_bib0093","doi-asserted-by":"crossref","first-page":"477","DOI":"10.21037\/atm-22-1572","article-title":"Operable hepatitis B virus-related hepatocellular carcinoma: gut microbiota profile of patients at different ages","volume":"10","author":"Peng","year":"2022","journal-title":"Ann Transl Med"},{"issue":"12","key":"10.1016\/j.clinre.2026.102874_bib0094","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1111\/cas.15983","article-title":"Gut microbiome as a biomarker for predicting early recurrence of HBV-related hepatocellular carcinoma","volume":"114","author":"Zheng","year":"2023","journal-title":"Cancer Sci"},{"issue":"4","key":"10.1016\/j.clinre.2026.102874_bib0095","first-page":"230","article-title":"Effect of transarterial chemotherapy on the structure and function of gut microbiota in New Zealand white rabbits","volume":"13","author":"Bai","year":"2024","journal-title":"Biology (Basel)"},{"issue":"9","key":"10.1016\/j.clinre.2026.102874_bib0096","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.4049\/jimmunol.1701723","article-title":"Cutting edge: mitochondrial assembly of the NLRP3 inflammasome complex is initiated at priming","volume":"200","author":"Elliott","year":"2018","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.clinre.2026.102874_bib0097","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41419-020-2437-9","article-title":"Blocking GSDMD processing in innate immune cells but not in hepatocytes protects hepatic ischemia-reperfusion injury","volume":"11","author":"Li","year":"2020","journal-title":"Cell Death Dis"},{"issue":"6","key":"10.1016\/j.clinre.2026.102874_bib0098","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.3892\/etm.2021.10793","article-title":"CMPK2 accelerates liver ischemia\/reperfusion injury via the NLRP3 signaling pathway","volume":"22","author":"Luo","year":"2021","journal-title":"Exp Ther Med"},{"issue":"5","key":"10.1016\/j.clinre.2026.102874_bib0099","article-title":"Activation of NLRP3 inflammasome via Drp1 overexpression in Kupffer cells aggravates ischemia-reperfusion injury in hepatic steatosis","volume":"11","author":"Zhang","year":"2023","journal-title":"J Clin Transl Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2026.102874_bib0100","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41419-020-03347-3","article-title":"DHA\/AA alleviates LPS-induced Kupffer cells pyroptosis via GPR120 interaction with NLRP3 to inhibit inflammasome complexes assembly","volume":"12","author":"Fan","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.clinre.2026.102874_bib0101","article-title":"MCC950 Ameliorates acute liver injury through modulating macrophage polarization and myeloid-derived suppressor cells function","volume":"8","author":"Yan","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"10.1016\/j.clinre.2026.102874_bib0102","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/abbs\/gmab030","article-title":"Liver kinase B1 attenuates liver ischemia\/reperfusion injury via inhibiting the NLRP3 inflammasome","volume":"53","author":"Dai","year":"2021","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"10.1016\/j.clinre.2026.102874_bib0103","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102305","article-title":"XBP1 deficiency promotes hepatocyte pyroptosis by impairing mitophagy to activate mtDNA-cGAS-STING signaling in macrophages during acute liver injury","volume":"52","author":"Liu","year":"2022","journal-title":"Redox Biol"},{"key":"10.1016\/j.clinre.2026.102874_bib0104","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.trsl.2024.03.006","article-title":"Genetic and pharmacological targeting of XBP1 alleviates hepatic ischemia reperfusion injury by enhancing FoxO1-dependent mitophagy","volume":"272","author":"Kuang","year":"2024","journal-title":"Transl Res"},{"key":"10.1016\/j.clinre.2026.102874_bib0105","article-title":"Integrated microbiome and metabolome analysis reveals the interaction between intestinal flora and serum metabolites as potential biomarkers in hepatocellular carcinoma patients","volume":"13","author":"Li","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"10.1016\/j.clinre.2026.102874_bib0106","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3390\/toxins15040293","article-title":"Microcystins exposure associated with blood lipid profiles and dyslipidemia: a cross-sectional study in Hunan Province, China","volume":"15","author":"Feng","year":"2023","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.clinre.2026.102874_bib0107","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.freeradbiomed.2020.09.015","article-title":"PINK1-mediated mitophagy protects against hepatic ischemia\/reperfusion injury by restraining NLRP3 inflammasome activation","volume":"160","author":"Xu","year":"2020","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"10.1016\/j.clinre.2026.102874_bib0108","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.apsb.2021.05.029","article-title":"The gut microbial metabolite, 3,4-dihydroxyphenylpropionic acid, alleviates hepatic ischemia\/reperfusion injury via mitigation of macrophage pro-inflammatory activity in mice","volume":"12","author":"Li","year":"2022","journal-title":"Acta Pharm Sin B"},{"issue":"5","key":"10.1016\/j.clinre.2026.102874_bib0109","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jcmgh.2023.01.004","article-title":"Gut microbiota-derived glutamine attenuates liver ischemia\/reperfusion injury via macrophage metabolic reprogramming","volume":"15","author":"Lu","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.clinre.2026.102874_bib0110","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jhep.2025.10.008","article-title":"Microbial metabolism dysfunction induced by transarterial chemoembolization aggravates postprocedural liver injury in HCC","volume":"84","author":"Li","year":"2026","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.clinre.2026.102874_bib0111","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/hep.29306","article-title":"Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial","volume":"66","author":"Bajaj","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.clinre.2026.102874_bib0112","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2024.12.047","article-title":"Microbiota transplant for hepatic encephalopathy in cirrhosis: the THEMATIC trial","volume":"83","author":"Bajaj","year":"2025","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.clinre.2026.102874_bib0113","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0321189","article-title":"Study protocol: fecal microbiota transplant combined with Atezolizumab\/Bevacizumab in patients with hepatocellular Carcinoma who failed to achieve or maintain objective response to Atezolizumab\/Bevacizumab - the FAB-HCC pilot study","volume":"20","author":"Pomej","year":"2025","journal-title":"PLoS One"},{"issue":"16","key":"10.1016\/j.clinre.2026.102874_bib0114","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e34385","article-title":"CircRNA-Phf21a_0002 promotes pyroptosis to aggravate hepatic ischemia\/reperfusion injury by sponging let-7b-5p","volume":"10","author":"Jiang","year":"2024","journal-title":"Heliyon"},{"issue":"12","key":"10.1016\/j.clinre.2026.102874_bib0115","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.7150\/thno.96928","article-title":"Single cell RNA-sequencing delineates CD8(+) tissue resident memory T cells maintaining rejection in liver transplantation","volume":"14","author":"Li","year":"2024","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.clinre.2026.102874_bib0116","first-page":"35","article-title":"Predictors of liver failure after transarterial chemoembolization in patients with spontaneously ruptured hepatocellular carcinoma: a retrospective study","volume":"6","author":"Deng","year":"2023","journal-title":"J Interv Med"},{"issue":"17","key":"10.1016\/j.clinre.2026.102874_bib0117","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.3390\/cancers13174325","article-title":"Effect of transarterial chemoembolization on ALBI grade in intermediate-stage hepatocellular carcinoma: criteria for unsuitable cases selection","volume":"13","author":"Chi","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.clinre.2026.102874_bib0118","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/s12876-022-02366-y","article-title":"Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization","volume":"22","author":"Ananchuensook","year":"2022","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"10.1016\/j.clinre.2026.102874_bib0119","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40644-023-00575-6","article-title":"Validation of the ALBI-TAE model and comparison of seven scoring systems for predicting survival outcome in patients with intermediate-stage hepatocellular carcinoma undergoing chemoembolization","volume":"23","author":"Bannangkoon","year":"2023","journal-title":"Cancer Imaging"},{"issue":"Suppl 1","key":"10.1016\/j.clinre.2026.102874_bib0120","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.acra.2023.05.014","article-title":"Machine learning-based development of nomogram for hepatocellular carcinoma to predict acute liver function deterioration after drug-eluting beads transarterial chemoembolization","volume":"30","author":"Li","year":"2023","journal-title":"Acad Radiol"},{"issue":"1","key":"10.1016\/j.clinre.2026.102874_bib0121","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1148\/radiol.2018180257","article-title":"A predictive model for postembolization syndrome after transarterial hepatic chemoembolization of hepatocellular carcinoma","volume":"290","author":"Khalaf","year":"2019","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.clinre.2026.102874_bib0122","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1038\/s41598-024-53711-y","article-title":"Development of a predictive nomogram for postembolization syndrome after transcatheter arterial chemoembolization of hepatocellular carcinoma","volume":"14","author":"Bai","year":"2024","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.clinre.2026.102874_bib0123","first-page":"817","article-title":"Managing postembolization syndrome through a machine learning-based clinical decision support system: a randomized controlled trial","volume":"42","author":"Kang","year":"2024","journal-title":"Comput Inform Nurs"},{"key":"10.1016\/j.clinre.2026.102874_bib0124","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.678847","article-title":"Superselective transarterial chemoembolization for unresectable or \"ablation unsuitable\" hepatocellular carcinoma in the caudate lobe: a real world, single-center retrospective study","volume":"11","author":"Yan","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.clinre.2026.102874_bib0125","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jvir.2021.10.015","article-title":"A transarterial chemoembolization of balloon-occluded alternate infusions of cisplatin and gelatin particles for hepatocellular carcinoma: a phase I\/II multicenter prospective study of safety and efficacy","volume":"33","author":"Hoshiai","year":"2022","journal-title":"J Vasc Interv Radiol"},{"issue":"4","key":"10.1016\/j.clinre.2026.102874_bib0126","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2214\/AJR.20.24708","article-title":"Imaging changes and clinical complications after drug-eluting bead versus conventional transarterial chemoembolization for unresectable hepatocellular carcinoma: multicenter study","volume":"217","author":"Zhang","year":"2021","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.clinre.2026.102874_bib0127","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s41747-021-00204-6","article-title":"Transarterial chemoembolisation in patients with hepatocellular carcinoma: low-dose doxorubicin reduces post-embolisation syndrome without affecting survival-prospective interventional study","volume":"5","author":"Bessar","year":"2021","journal-title":"Eur Radiol Exp"},{"issue":"5","key":"10.1016\/j.clinre.2026.102874_bib0128","doi-asserted-by":"crossref","first-page":"890","DOI":"10.3748\/wjg.v29.i5.890","article-title":"Efficacy of dexamethasone and N-acetylcysteine combination in preventing post-embolization syndrome after transarterial chemoembolization in hepatocellular carcinoma","volume":"29","author":"Simasingha","year":"2023","journal-title":"World J Gastroenterol"},{"issue":"31","key":"10.1016\/j.clinre.2026.102874_bib0129","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v31.i31.109630","article-title":"Efficacy of N-acetylcysteine vs dexamethasone in preventing postembolization syndrome post-transarterial chemoembolization in hepatocellular carcinoma: a randomized controlled trial","volume":"31","author":"Koonsiripaiboon","year":"2025","journal-title":"World J Gastroenterol"},{"issue":"10","key":"10.1016\/j.clinre.2026.102874_bib0130","doi-asserted-by":"crossref","first-page":"1514.e5","DOI":"10.1016\/j.cmi.2021.01.014","article-title":"Association between prophylactic antibiotic use for transarterial chemoembolization and occurrence of liver abscess: a retrospective cohort study","volume":"27","author":"Yoshihara","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clinre.2026.102874_bib0131","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.2147\/CMAR.S303172","article-title":"The risk assessment and clinical research of bile duct injury after transcatheter arterial chemoembolization for hepatocellular carcinoma","volume":"13","author":"Xu","year":"2021","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1016\/j.clinre.2026.102874_bib0132","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1186\/s12885-024-12864-9","article-title":"Predictors and risk factors of bile duct injury after transcatheter arterial chemoembolization for hepatocellular carcinoma","volume":"24","author":"Lu","year":"2024","journal-title":"BMC Cancer"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740126001208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740126001208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:45:38Z","timestamp":1788223538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740126001208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":132,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2210740126001208"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2026.102874","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TACE-induced liver injury in hepatocellular carcinoma: mechanisms, prediction, and prevention in the era of gut microbiota and inflammasome research","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2026.102874","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102874"}}